Decreased lung ischemia-reperfusion injury in rats after preoperative administration of cyclosporine and tacrolimus  by Krishnadasan, B. et al.
Decreased lung ischemia-reperfusion injury in rats after




A. L. Farr, BA
A. Barnes, PharmD
E. D. Verrier, MD
M. S. Mulligan, MD
Objectives: Calcineurin inhibitors reduce experimental reperfusion injury in the
liver, brain, heart, kidney, and small bowel. These studies were undertaken to
determine whether these agents are similarly protective against lung ischemia-
reperfusion injury.
Methods: Left lungs of male rats were rendered ischemic for 90 minutes and
reperfused for as long as 4 hours. Treated animals received cyclosporine A (INN:
ciclosporin; 1 or 5 mg/kg) or tacrolimus (0.2 mg/kg) 6 hours before ischemia, at
reperfusion, or 2 hours after reperfusion. Injury was quantitated in terms of tissue
polymorphonuclear leukocyte accumulation (myeloperoxidase content), vascular
permeability (iodine 125–labeled bovine serum albumin extravasation), and bron-
choalveolar lavage leukocyte content. Separate tissue samples were processed for
nuclear protein and cytokine messenger RNA.
Results: Treatment with cyclosporine (5 mg/kg) or tacrolimus (0.2 mg/kg) 6 hours
before reperfusion reduced lung vascular permeability by 54% and 56% relative to
control animals (P  .03). The protective effects of cyclosporine and tacrolimus
treatment before reperfusion correlated with 42% and 43% reductions in tissue
polymorphonuclear leukocyte (myeloperoxidase) content (P  .008) and marked
reductions in bronchoalveolar lavage leukocyte accumulation (P  .01). Adminis-
tration of cyclosporine or tacrolimus at the time of reperfusion or 2 hours into the
reperfusion period offered little or no protection. Animals treated before reperfusion
also demonstrated marked reductions in nuclear factor B activation and expression
of proinflammatory cytokine messenger RNA.
Conclusion: Cyclosporine and tacrolimus treatment before reperfusion was protec-
tive against lung ischemia-reperfusion injury in rats. The mechanism of these
protective effects may involve the inhibition of nuclear factor B, a central tran-
scription factor mediating inflammatory injury. The decreased expression of cyto-
kine messenger RNA indicates that both cyclosporine and tacrolimus may exert
their protective effects at the pretranscriptional level.
Lung reperfusion injury occurs in as many as 25% of human lungtransplant recipients.1 Efforts to alleviate reperfusion injury havefocused on altering native host defenses,2 improving preservationtechniques,3 and minimizing ischemic times. However, lung reper-fusion injury remains a problem and may increase the occurrence ofacute and chronic rejection by enhancing allograft major histocom-
patibility complex II expression.
Cyclosporine A (CSA, INN: ciclosporin) and tacrolimus are immunosuppressive
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agents that have been used in solid-organ transplantation for
2 decades. The immunomodulatory effects of CSA and
tacrolimus involve the inhibition of the protein tyrosine
phosphatase calcineurin (Figure 1). CSA is a hydrophobic
undecapeptide that forms a complex with the cytoplasmic
protein cyclophilin that inhibits calcineurin. Tacrolimus is a
macrolide antibiotic that binds to a similar cytoplasmic
protein, FK-binding protein, and blocks calcineurin 100
times more effectively than does the CSA-cyclophilin com-
plex. The inhibition of calcineurin in turn reduces the ex-
pression of a number of nuclear transcription factors, in-
cluding nuclear factor (NF) AT, Oct-1, AT-1, and NF-B.
All these transcription factors can bind to different se-
quences on the interleukin-2 promoter. By far the most
critical, however, is NF-AT. Decreased nuclear transcrip-
tion factor activity then results in a diminished production
of interleukin-2 messenger RNA and protein, which subse-
quently blunts the T-cell response that mediates cellular
rejection.
Whereas inhibition of NF-AT may be central to the
immunomodulatory effects of CSA and tacrolimus, block-
ade of NF-B may have broader anti-inflammatory effects.
NF-B has a range of activities, including modulation of
cell growth and death, regulation of immune function, and
apparent effects on acute reperfusion injury.4 The ability of
CSA and tacrolimus to block NF-B activation during acute
cardiac reperfusion injury has been demonstrated.5 CSA and
tacrolimus have also been shown to reduce acute reperfu-
sion injury of the liver 6,7 and small bowel,8 but the mech-
anism mediating these protective effects has not been elu-
cidated, and their impact on transcriptional regulation in this
setting is unknown. At present no data exist regarding the
effects of CSA or tacrolimus on lung ischemia-reperfusion
injury.
In vitro studies have delineated the mechanism by which
CSA and tacrolimus may inhibit NF-B activation.9,10
These studies suggest that inhibition of calcineurin blocks
the degradation of I-B, the cytoplasmic protein that binds
NF-B in its inactive form. In addition, processing of pro-
form precursors of NF-B to its functional heterodimeric
form may be inhibited. The net result is a diminished
concentration of active NF-B in the nucleus, which leads
to decreased production of messenger RNA for proinflam-
matory cytokines, neutrophil adhesion molecules, proco-
agulant proteins, and vasoconstrictive substances. The re-
duction in NF-B activation and subsequent anti-
inflammatory effects therefore appear to act through
mechanisms that are distinct from the immunomodulation
that occurs through NF-AT inhibition.
Studies of calcineurin inhibition during organ ischemia-
reperfusion injury have methodologic problems that make
clinical correlation difficult. Most animal studies investigat-
ing the effects of CSA and tacrolimus delivered the drugs
during the week preceding the experiment to ensure that the
animals had adequate drug levels before the ischemic in-
sult.6-8 Although this strategy was protective in these mod-
Figure 1. Immunomodulatory effects of CSA and tacrolimus (TAC). With antigen presentation, protein kinase C (PKC)
activation leads to production of calcineurin, phophatase increasing production of various transcription factors,
including NF-AT, OCT-1, AT-1, and NF-B. Increase in NF-AT results in transcription of IL-2, powerful T-cell
stimulant driving rejection. CSA and tacrolimus block this reaction by binding with cyclophilin and FK-binding
protein to inhibit action of calcineurin.
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els, it would be difficult to treat human transplant recipients
accordingly, because the date of transplantation is deter-
mined by donor organ availability and therefore is unpre-
dictable. One study that did administer the drug just before
cardiac reperfusion demonstrated some protective effects
that were dose dependent.5
We hypothesized that administration of CSA or tacroli-
mus would be protective in lung ischemia-reperfusion in-
jury. Furthermore, treatment several hours before the isch-
emic insult might enhance the protective effects relative to
treatment just before reperfusion or after it has begun. This
would be akin to dosing patients as soon as an appropriate
donor organ has been identified. In addition, we considered
it important to investigate doses of CSA and tacrolimus that
would be appropriate for human recipients. Previous animal
studies have administered CSA at 10 to 25 mg/kg orally
across 3 to 4 days or 5 mg/kg subcutaneously over 1
week.6-8 Such dosing schedules might be nephrotoxic or
otherwise detrimental if applied to human recipients. Fi-
nally, knowing that CSA and tacrolimus attenuate reperfu-
sion injury in heart, liver, and small bowel, and that in vitro
studies indicate that these effects may be mediated through
NF-B blockade, we hypothesized that protective effects of
these drugs would be associated with a demonstrable reduc-
tion in NF-B activation.
Material and Methods
Reagents
Commercial preparations of CSA (Novartis Pharmaceuticals Cor-
poration, East Hanover, NJ) and tacrolimus (Fujisawa Healthcare,
Inc, Deerfield, Ill) were obtained from the inpatient pharmacy at
the University of Washington. All other reagents were purchased
from Sigma (St Louis, Mo) unless otherwise specified.
Animal Model
Pathogen-free adult male Long-Evans rats (Simonsen Laborato-
ries, Inc, Gilroy, Calif) weighing 280 to 320 g were used for all
experiments. The University of Washington Animal Care Com-
mittee approved all experimental protocols. Animals were anes-
thetized with 30 to 35 mg of intraperitoneally administered pen-
tobarbital, shaved, and prepared for surgery. A 14-gauge
angiocatheter was inserted into the trachea through a midline neck
incision and secured with a 4–0 braided suture. Animals were then
placed on a Harvard Rodent Ventilator (Harvard Apparatus, Inc,
Holliston, Mass) with an inspired oxygen content of 60%, a rate of
80 breaths/min, and 2 cm H2O of positive end-expiratory pressure.
Maximal peak pressures were maintained below 10 cm H2O. All
animals received 0.4 mg atropine intramuscularly, and anesthesia
was maintained with inhaled halothane. Dissection was conducted
with an operating microscope, and a warming blanket was placed
underneath each animal throughout the experiment.
A left anterolateral thoracotomy in the fifth intercostal space
was performed. The left lung was mobilized atraumatically, and
the inferior pulmonary ligament was divided sharply. Animals then
received 50 units of intravenous heparin in saline solution (total
volume 500 L). Five minutes after heparin was administered, the
left pulmonary artery, veins, and main stem bronchus were oc-
cluded with a noncrushing microvascular clamp. During the ex-
periment the lungs were kept moist with periodic application of
warm isotonic sodium chloride solution, and the incision was
covered to minimize evaporative losses. The period of ischemia
was constant at 90 minutes. At the end of the ischemic period the
clamp was removed from the hilum, and the lung was allowed to
ventilate and reperfuse for periods as long as 4 hours. Animals
received subcutaneously 0.5 mL warm saline solution per hour to
maintain hydration during the experiment. At the end of the
reperfusion period a midline incision from the neck to the pubis
was made to allow access to the chest and abdomen. Blood
samples were obtained from the inferior vena cava just before the
animal was killed. The heart-lung block was rapidly excised, and
the pulmonary circulation was flushed through the main pulmo-
nary artery with 20 mL isotonic sodium chloride solution. The
lungs were then separated from the heart and mediastinal tissues
and analyzed as outlined here. A time-matched sham control group
underwent the same procedure except that the microvascular
clamp was not applied to the hilum (thoracotomy alone).
Treated animals received CSA intravenously at 1 mg/kg or 5
mg/kg or tacrolimus intravenously at 0.2 mg/kg. Drugs were
mixed in 500 L of sterile phosphate-buffered saline solution just
before administration and then injected through the penile vein 5
minutes before reperfusion or 2 hours after removal of the hilar
clamp. Additional groups of animals were treated with intravenous
CSA or tacrolimus 6 hours before the beginning of the experiment.
A control group of animals received cremaphor vehicle (the sol-
vent for CSA and tacrolimus) at matched time points.
Lung Permeability Index
To quantitate lung injury related to ischemia and reperfusion, a
lung permeability index was determined in the following manner.
Iodine 125–radiolabeled bovine serum albumin (125I-BSA) was
obtained from NEN Life Science Products, Inc (Boston, Mass).
Before use of the 125I-BSA in vivo, serial dilutions were performed
to obtain an activity of 800,000 counts/min (cpm) per dose. This
volume of 125I-BSA, approximately 2 L of the stock solution,
was then brought to a final volume of 500 L in a 1% BSA and
phosphate-buffered saline solution. Five minutes before removal
of the hilar clamp or at an equivalent time in the sham control
group, the 125I-BSA preparation was intravenously injected. Im-
mediately before the animal was killed, 1 mL blood was drawn
from the inferior vena cava. The heart-lung block was then excised
and flushed as described previously. The radioactivity was then
quantitated for the left and right lungs and for inferior vena cava
blood with a gamma counter. The permeability index was then
expressed as the ratio of the cpm in the left lung to the cpm in 1.0
mL of inferior vena caval blood as follows: permeability index 
cpm in left lung/cpm in 1.0 mL blood. This ratio corrected for any
variation in systemic blood levels of radioactivity and provided a
reproducible measure of lung microvascular permeability.
Myeloperoxidase Assay
Tissue myeloperoxidase (MPO) content was used to quantitate
neutrophil accumulation in the lungs. After flushing, the pulmo-
nary circulation the lungs were homogenized for 60 seconds in a
solution of 0.5% hexadecyltrimethylammonium bromide and
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5-mmol/L ethylenediaminetetraacetic acid (EDTA) in 50-mmol/L
potassium-phosphate buffer (pH 6.0). Samples were then sonicated
for 40 seconds in four 10-second bursts. The homogenized tissue
was maintained on ice between all tissue processing steps. Samples
were then centrifuged at 2300g for 30 minutes at 4°C and the
supernatants were recovered. Assay buffer was composed of
0.0005% hydrogen peroxide and 0.167-mol/L o-dianisidine dihy-
drochloride in 100-mmol/L potassium phosphate buffer (pH 6.0).
A 50-L aliquot of each sample was mixed with 1.45 mL of assay
buffer, and the change in absorbence at 460 nm over 1 minute was
recorded.
Broncheoalveolar Lavage
Additional animals underwent bronchoalveolar lavage (BAL) at
the time they were killed. Through an extended median sternot-
omy, a 14-gauge angiocatheter was placed and the lungs were
lavaged individually with 3.0 mL cold sterile saline solution.
Individual lung BAL analysis was accomplished by clamping the
contralateral hilum. At least 80% of the instilled fluid was recov-
ered from each lung. This fluid was centrifuged (1500g for 8
minutes at 4°C) to pellet the cells. The red blood cells were lysed,
and the pellet was resuspended in isotonic sodium chloride solu-
tion. Cells were then counted and a differential count was deter-
mined with a hemocytometer (Hausser Scientific Partnership, Hor-
sham, Pa).
Electrophoretic Mobility Shift Assay
Additional left lungs were snap frozen at the end of the experi-
mental protocols. These frozen tissue samples were ground into a
fine powder and then suspended in 4.0 mL buffer containing
0.06% Nonidet P-40 (Sigma Chemical Co, St Louis, Mo), 150-
mmol/L sodium chloride, 10-mmol/L N-2-hydroxyethylpipera-
zine-N-2-ethanesulfonic acid (HEPES), 1-mmol/L EDTA, and 0.5-
mmol/L phenylmethylsulfonyl fluoride (PMSF). The solution was
then homogenized and centrifuged for 15 seconds at 12,000g. The
pellet was discarded, and the supernatant was cooled to 4°C. The
supernatant was then centrifuged again for 15 seconds at 12,000g.
The resultant pellet was suspended in 40-L buffer containing
40-mmol/L sodium chloride, 20-mmol/L HEPES, 0.2-mmol/L
EDTA, 1.2-mmol/L magnesium chloride, 0.5-mmol/L PMSF, 0.5-
mmol/L dichlorodiphenyltrichloroethane, 25% glycerol, 5-g/mL
aprotinin, and 5-g/mL leupeptin at 4°C for 20 minutes. This
solution was then centrifuged for 5 minutes, the pellet was dis-
carded, and the supernatant containing the nuclear protein was
stored at –70°C. Quantification of nuclear protein was performed
with the bichinoic acid assay.
A 10 g sample of nuclear protein was incubated in a binding
reaction with a double-stranded phosphorus 32–end-labeled oli-
gonucleotide containing the human consensus NF-B binding se-
quence 5-GCCATTGGGGATTTCCTCTTTACTGG-3. This se-
quence is identical to the rat consensus NF-B site. The binding
reaction was carried out at room temperature for 60 minutes, and
the proteins were resolved on a 6% nondenaturing polyacrylamide
gel at 100 V for 1 to 2 hours. The gels were dried and autoradio-
graphed. Triplicate samples for each specimen were analyzed.
Densitometry was performed with ImageJ software (version 1.2;
Research Services Branch, National Institute of Mental Health,
Bethesda, Md) to assess relative signal intensity.
Ribonuclease Protection Assay
Lung RNA was isolated in guanidine thiocyanate, with two rounds
of acid phenol and chloroform extraction and alcohol precipitation.
RNA integrity was confirmed by agarose gel electrophoresis and
quantitated by optical density measurements at 260 nm. RNA from
each lung was evaluated with the Riboquant system (BD Phar-
Mingen, San Diego, Calif); rat cytokine template was used for
detection of cytokines. In vitro transcription was carried out in
transcription buffer supplemented with uridine triphosphate la-
beled with -phosphorus 32 (3000 Ci/mmol; Amersham Pharma-
cia Biotech, Inc, Piscataway, NJ) and T7 RNA polymerase. After
deoxyribonuclease I treatment, the riboprobe was isolated by phe-
nol and chloroform extraction and ammonium and ethanol precip-
itation. Labeling efficiency was determined by measuring Cherno-
kov activity in a scintillation counter. Each riboprobe was diluted
to the optimal activity (defined by the manufacturer), added to 20
g of kidney RNA, heated to 90°C, allowed to cool to 56°C, and
annealed overnight. After ribonuclease and proteinase K treatment,
protected RNA hybrids were purified by phenol and chloroform
extraction and ammonium acetate and ethanol precipitation and
then separated by electrophoresis on 5% polyacrylamide/8-mol/L
urea gels. Gels were dried and subjected to autoradiography with
Kodak Biomax MS2 Film (Eastman Kodak Company, Rochester,
NY). Triplicate samples for each specimen were analyzed. Densi-
tometric analysis was done with ImageJ software (version 1.2).
Statistical Analysis
All data were presented as mean  SEM unless otherwise desig-
nated. Comparisons between multiple groups were made with
analysis of variance. Comparisons between individual groups were
made with a 2-tailed Student t test.
Results
Four different control groups were generated. Negative con-
trol animals were those that did not undergo any surgical
manipulation. Sham (thoracotomy only) control animals
were placed on the ventilator and underwent a left thora-
cotomy and as long as 5.5 hours of mechanical ventilation
but without occlusion of the hilum. A third group underwent
thoracotomy and the occlusion of left hilum for 90 minutes.
These animals were killed before any reperfusion. The final
group was subjected to 90 minutes of ischemia followed by
4 hours of reperfusion (Figure 2). The permeability index in
animals undergoing thoracotomy alone (0.18  0.02) was
double that seen in unmanipulated lungs (0.09 0.006, P
.04). Animals that were subjected to 90 minutes of ischemia
without reperfusion demonstrated increases in permeability
that were not significantly different from the sham thora-
cotomy control group (0.18  0.02 vs 0.22  0.005, P 
.20). However, a marked increase in permeability was seen
in animals that underwent 4 hours of reperfusion after 90
minutes of ischemia (0.75  0.01, P  .001 relative to
unmanipulated control group).
Positive control animals that received phosphate-buff-
ered saline solution had a mean permeability index of
0.75  0.01, and those receiving Cremaphor vehicle had a
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mean index of 0.76  0.03 (Figure 3). Animals that re-
ceived CSA or tacrolimus 2 hours after reperfusion did not
demonstrate any reduction in vascular permeability relative
to positive control animals. In contrast, treatment at the time
of reperfusion (Figure 3) reduced permeability by 17% in
animals receiving CSA at 5 mg/kg (P  .03) and by 18% in
animals treated with tacrolimus at 0.2 mg/kg (P  .04).
Administration of low-dose CSA (1 mg/kg) at reperfusion
provided no protection relative to positive control animals.
Treatment with tacrolimus or CSA at either dose 6 hours
before the initiation of the experiment decreased lung injury
significantly (Figure 3). The permeability index in animals
pretreated with CSA at 1 mg/kg was reduced by 33% (P 
.008); with CSA at 5 mg/kg the reduction was 54% (P 
.004), and with tacrolimus at 0.2 mg/kg the reduction was
56% (P  .003). Thus advance treatment with CSA and
tacrolimus offered greater and more consistent protection
than did treatment at the time of reperfusion or 2 hours after
reperfusion had begun.
MPO Activity
MPO activity was measured in lungs from unmanipulated
control animals and in lungs from animals subjected to 90
minutes of ischemia and 0, 1, 2, 3, and 4 hours of reperfu-
sion (Figure 4). The change in absorbence at 460 nm across
1 minute in unmanipulated control animals was 0.06 
0.002. With ischemia only, MPO activity increased only
slightly and not statistically significantly relative to unma-
nipulated control animals (0.09  0.01).
Reperfusion was associated with a steady increase in
MPO activity that was detectable at 2 hours after reperfu-
sion and marked by 3 (0.26  0.01) and 4 hours (0.41 
0.04, P  .002; Figure 4). In an additional experiment with
an extended time course, the tissue MPO content did not
continue to increase at 6 or 8 hours and began to decrease at
12 hours (data not shown). MPO content thus appeared to
peak after 4 hours of reperfusion.
MPO analysis was performed on lungs from animals that
received CSA at 5 mg/kg 6 hours before ischemia, at the
time of reperfusion, or 2 hours after the onset of reperfusion.
MPO was also assessed in lungs from animals that received
tacrolimus at 0.2 mg/kg 6 hours before ischemia (Figure 5).
A statistically significant decrease in MPO content was seen
only among animals that were treated in advance with CSA
or tacrolimus. Animals treated with CSA or tacrolimus 6
hours before ischemia demonstrated 38% and 36% de-
creases in tissue neutrophil accumulation, respectively (P
.008). Treatment with CSA or tacrolimus at the time of
reperfusion or 2 hours after the onset of reperfusion was not
associated with a reduction in lung MPO.
BAL Leukocyte Content
BAL analysis was undertaken to evaluate leukocyte content
in the distal airways and alveolar compartment. Baseline
BAL leukocyte counts were recorded in four groups: unma-
nipulated control group, sham thoracotomy control group,
ischemia-alone control group (90 minutes of ischemia
alone), and reperfusion injury group (90 minutes of isch-
emia followed by 4 hours of reperfusion; Figure 6). Animals
undergoing sham thoracotomy or ischemia alone did not
demonstrate a significant increase in BAL leukocyte con-
tent. However, a statistically significant increase in BAL
leukocyte content was seen after 4 hours of reperfusion
(P  .005). The predominant cell type at the end of the
reperfusion period in this group was the neutrophil, whereas
all the other groups demonstrated mainly alveolar macro-
phages (95%).
As seen with tissue neutrophil accumulation, BAL cell
count was reduced only in animals treated before ischemia
with CSA or tacrolimus (Figure 6). Treatment at the time of
reperfusion or 2 hours later did not reduce BAL leukocyte
count (162  14 and 146  15, respectively). In animals
receiving CSA or tacrolimus 6 hours before ischemia, the
BAL leukocyte count was 32% lower than the positive
control values (P  .01).
Electrophoretic Mobility Shift Assay Analysis for
NF-B
Shown in Figure 7 is a representative electrophoretic mo-
bility shift assay (EMSA) that details the expression of
NF-B in the nucleus of control and treated left lungs. There
was no NF-B detected in the negative control animals. In
contrast, significant activation of NF-B was apparent in the
animals that underwent ischemia and reperfusion. The band
specific for NF-B was delineated with a nonradiolabeled
(cold) oligonucleotide. The location of this band is demon-
strated in the lane marked “cold competition.” Animals that
received treatment before ischemia with CSA and tacroli-
mus appeared to have attenuated NF-B expression in the
nucleus. These differences are quantitated in the densito-
metric analysis depicted below the autoradiograph.
Figure 2. Left lung permeability in control animals. Lung vascular
permeability was increased 7-fold in animals that underwent
ischemia and reperfusion (P < .001). Animals that underwent
thoracotomy alone and ischemia alone also had statistically
significant increases in permeability relative to unmanipulated
control animals (P < .04; n  4 in all experimental groups).
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Ribonuclease Protection Assay
Ribonuclease protection assays were performed on lung
extracts from four experimental groups, unmanipulated neg-
ative control animals, animals that underwent 90 minutes of
ischemia and 4 hours of reperfusion, and animals that un-
derwent ischemia and reperfusion after advance treatment
with CSA at 5 mg/kg or tacrolimus at 0.2 mg/kg (Figure 8).
In unmanipulated control animals there were few transcrip-
tional products in the left lung. In contrast, animals that
underwent ischemia and reperfusion of the left lung dem-
onstrated significantly increased messenger RNA expres-
sions for a variety of cytokines (IL-3, IL-5, IL-1, tumor
necrosis factor  (TNF-), IL-2, and interferon ). The
housekeeping genes demonstrated similar activities in all
lanes and are shown at the bottom of the gel. This indicates
that loading was equal, and relative differences in cytokine
messenger RNA expressions assessed by densitometry are
therefore meaningful and valid. In injured lungs from ani-
mals treated before ischemia with CSA or tacrolimus, there
were decreased expressions of several inflammatory and
Figure 4. MPO content in control animals. There was steady increase in MPO contents of left lungs with increasing
time of reperfusion. MPO content at 4 hours was statistically increased from unmanipulated control animals (P <
.002). Each experimental group included 4 animals.
Figure 3. Lung permeability in animals receiving CSA at 1 mg/kg, CSA at 5 mg/kg, and tacrolimus at 0.2 mg/kg. Two
groups of positive control animals are shown, one receiving saline solution and one receiving cremaphor vehicle.
There was no difference in permeability between these two groups. Animals treated 2 hours into reperfusion
(diagonally filled bars) did not demonstrate any significant reduction in lung vascular injury at either dose of CSA
or with tacrolimus (n  6 in all experimental groups). Animals treated at reperfusion (shaded bars) with 5 mg/kg
CSA and/or 0.2 mg/kg tacrolimus showed 17% and 18% reductions in lung vascular permeability (asterisk indicates
P < .05). Animals treated 6 hours before reperfusion (dotted bars) with CSA at 1 and 5 mg/kg and with tacrolimus
at 0.2 mg/kg demonstrated 33%, 54%, and 56% reductions in lung permeability (double asterisk indicates P < .003).
Krishnadasan et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 123, Number 4 761
CS
P
regulatory cytokines relative to positive control lungs.
These differences were quantitated in the densitometric
analysis shown in Figure 9.
Discussion
The utility of CSA and tacrolimus for induction and main-
tenance immunosuppressive therapy after solid-organ trans-
plantation has been demonstrated during the past 20
years.11 The immunomodulatory effects are mediated
through transcriptional blockade of IL-2 production.
These studies explored the possibility that these cal-
cineurin inhibitors regulate inflammatory effects through
a different transcriptional mechanism. One isolated study
demonstrated that administration of CSA after reperfu-
Figure 5. MPO activity in treated animals. Tissue neutrophil accumulation was modestly decreased in animals
receiving CSA at 5 mg/kg 2 hours after reperfusion and just before reperfusion, but decrease was not significant
(ns). Animals that received CSA at 5 mg/kg and tacrolimus (TAC) at 0.2 mg/kg 6 hours before experiment
demonstrated 38% and 36% decreases in MPO content, respectively. These were statistically significant (P < .008).
Each experimental group included 4 animals.
Figure 6. BAL cell count increased significantly in those animals undergoing ischemia followed by reperfusion
relative to unmanipulated control animals (P < .005). Small increases in cell count were seen with thoracotomy
alone and with ischemia alone, but these increases were not significant. Predominant cell type in animals was
alveolar macrophage, and most cells in unperfused lungs were neutrophils. Each experimental group included 6
animals. No relative decrease in alveolar cell count was seen in animals that received CSA at 5 mg/kg after 2 hours
of reperfusion or at time of reperfusion. However, significant decrease in alveolar leukocyte accumulation was
seen in animals that received CSA at 5 mg/kg and tacrolimus (TAC) at 0.2 mg/kg 6 hours before experiment,
resulting in 32% increase in BAL cell counts. Asterisk indicates P < .01.
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sion was protective against cardiac ischemia-reperfusion
injury.12 This group studied isolated rabbit hearts that
were perfused with buffer on a Langendorff apparatus.
The ischemic time was limited to 30 minutes, and CSA
was given 10 minutes into reperfusion. This is consistent
with our finding that some protection was afforded by
higher dose of CSA given at the time of reperfusion.
However, in our study lung vascular permeability was not
decreased in animals receiving CSA or tacrolimus after
the onset of reperfusion (Figure 3). This is supportive of
a transcriptional regulatory mechanism of action. Specif-
ically, CSA and tacrolimus may modulate ischemia and
reperfusion through blockade of NF-B. Ischemia alone
or ischemia followed by a short period of reperfusion
activates NF-B.13 Thus the blockade of NF-B activa-
tion would be most effective if the intervention were to
be performed before ischemia.
Protection from reperfusion injury is correlated with a
decreased expression of NF-B, as seen in the EMSA in
Figure 7. Selective blockade of TNF- with a polyclonal rat
anti–TNF- antibody afforded 45% protection from reper-
fusion injury, and combined blockade with anti–TNF– and
anti–IL-1 antibodies provided 60% protection (unpub-
lished data). The degree of protection offered by CSA or
TAC pretreatment (54%-56%) is therefore impressive.
Greater protection may be difficult to achieve because of
incomplete transcriptional blockade or redundancy in proin-
flammatory mediators released in the lung.
The protection from vascular injury seen with cal-
cineurin inhibitors administered 6 hours before ischemia
was correlated with a decrease in neutrophil accumulation
in both lung tissue and the alveolar compartment. Only
animals treated before ischemia with CSA or tacrolimus
demonstrated significant reductions in tissue neutrophil ac-
cumulation. These findings support conclusions of earlier
studies regarding the ability of CSA and tacrolimus to
reduce polymorphonuclear neutrophil accumulation in
reperfused heart and liver.5,14
The EMSA suggests that NF-B activation was blocked
in the animals that received CSA or tacrolimus before
ischemia. This is the first direct demonstration of NF-B
blockade by calcineurin inhibitors in an intact animal
model. Others have assumed that NF-B is involved be-
cause I-B activity is preserved with tacrolimus treatment.5
Multiple investigators have established that NF-B activa-
tion is decreased by calcineurin inhibitors in vitro.15,16 This
phenomenon has been investigated specifically in human
bronchial epithelial cells17 and suggests that these events
may be important in the development of acute lung inflam-
mation. Several mechanisms through which calcineurin in-
Figure 7. EMSA for nuclear protein expression of NF-B. A, Area of interest is boxed. Far left lane shows extract
from injured positive control lung that underwent ischemia followed by 4 hours of reperfusion. Second lane shows
unmanipulated negative control lung. Third lane shows another positive control for side-by-side comparison.
Fourth lane (Cold Competition) shows lung treated with nonradiolabeled NF-B oligonucleotide that antagonizes
radiolabeled oligonucleotide. Band specific for NF-B drops out at this time. Far right lanes demonstrate absence
of NF-B expression in animals treated with CSA and tacrolimus 6 hours before reperfusion. B, Densitometric
results corresponding to lanes on gel.
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hibitors may decrease NF-B activity have been postulated.
Calcineurin affects cellular kinetics and activation through
its action as a calcium- and calmodulin-dependent serine
and threonine phosphatase. It is believed that calcineurin
blockade results in the inactivation of the 20S proteasome.
The 20S proteasome is the site of degradation of I-B, the
cytoplasmic inhibitor of NF-B. Calcineurin also appears to
facilitate processing of NF-B proforms (p105) to the active
heterodimer (p65). The inactivation of the 20S proteasome
by calcineurin inhibitors thus results in the decreased pro-
duction of active NF-B and the preservation of cytoplas-
mic stores of I-B.
NF-B blockade by CSA and tacrolimus correlates with
the decreased expressions of phlogistic cytokine messenger
RNA seen with the ribonuclease protection assay. Pretran-
scriptional blockade of NF-B provided by CSA and ta-
crolimus would explain the diminution in expression of a
wide variety of cytokines. TNF- expression is regulated
through some NF-B–dependent mechanism.14 NF-B ac-
tivation has also been linked to the production of intracel-
lular adhesion molecule 1, P-selectin, and IL-8.18 The de-
creased production of these adhesion molecules,
chemokines, and cytokines seen with calcineurin inhibitors
therefore may result in the decreased leukocyte accumula-
tion seen in the tissue and alveolar compartment of the lung
(Figures 5 and 6). Ultimately, these effects may reflect the
amelioration of tissue injury seen with CSA and tacrolimus
treatment.
The protection provided by calcineurin inhibitors has
also been associated with inhibition of the mitochondrial
transition pore opening19,20 and with variable effects on
nitric oxide and endothelin metabolism.21,22 These mecha-
nisms may also be relevant in a model of lung ischemia-
reperfusion, and further investigation is needed to elucidate
the relevance of these pathways in this model. Most studies
of the mitochondrial transition pore have been done in
models of liver and heart reperfusion injury. Mitochondrial
transition pore changes may be more important in these
tissues than in the lung, because heart and liver appear to
have a higher concentration of mitochondria.
Protection afforded by calcineurin inhibitors may also be
mediated through amelioration of postischemic vasocon-
striction. Tacrolimus appears to preserve the activity of
inducible nitric oxide synthase during rat brain ischemia-
reperfusion injury,22 and both CSA and tacrolimus may
suppress endothelin 1 production in rat small-bowel isch-
emia-reperfusion.23 These mechanisms may be particularly
relevant to the pulmonary circulation, where amelioration of
postischemic vasoconstriction may improve ventilation-
perfusion mismatch and overall lung function.
CSA and tacrolimus can cause vasoconstriction in the
renal vascular bed.24 If such effects were seen in the pul-
monary circulation, alteration of Starling forces would limit
the edema seen with reperfusion injury. To characterize the
acute effects of CSA and tacrolimus on pulmonary vaso-
motor tone, pulmonary arterial pressures were measured in
rats after administration of the calcineurin inhibitors. Pul-
monary arterial pressures were not altered in animals re-
ceiving CSA or tacrolimus for 30 minutes after administra-
tion of the drug (data not shown). It thus appears that the
Figure 8. Ribonuclease protection assay. Four experimental
groups are shown: negative control, positive control, and animals
treated with 5 mg/kg CSA and 0.2 mg/kg tacrolimus (TAC) 6 hours
before reperfusion. Housekeeping genes shown at bottom of gel
demonstrate equal loading of RNA in all experimental groups.
IFN, Interferon.
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protective effects of CSA and tacrolimus are not related to
drug-induced pulmonary vasoconstriction.
The potential for use of CSA or tacrolimus as advance
treatment for human lung transplant recipients is contingent
on the ability to deliver an adequate dose of calcineurin
inhibitor at the appropriate time. Other studies have admin-
istered nephrotoxic doses of CSA (10–25 mg/kg) to animals
to demonstrate protective effects.6-8 In this study we treated
the study animals with clinically relevant doses of CSA (1
and 5 mg/kg intravenously) and tacrolimus (0.2 mg/kg).
Figure 9. Densitometric analyses for ribonuclease protection assay in Figure 8. Illustrated are samples from
negative control animals, positive control animals, and animals treated with 5 mg/kg CSA and 0.2 mg/kg tacrolimus
(TAC, FK-506) 6 hours before reperfusion. There were generalized decreases in expressions in treatment groups,
as seen quantitatively in densitometric analyses. IL-2 (A), TFN- (B), and interferon  (C) messenger RNA
expressions were decreased in animals treated with CSA and tacrolimus.
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Significant protection was associated with advance treat-
ment at both dose levels. CSA at 1 mg/kg is a dose that is
commonly used for patients with impaired creatinine clear-
ance, so the doses used in these studies appear to be both
clinically relevant and safe. Ultimately the effectiveness of
this particular treatment strategy needs to be systematically
studied in human beings.
In conclusion, advance treatment of rats with CSA and
tacrolimus decreased lung ischemia-reperfusion injury. The
protection afforded by calcineurin inhibitors was associated
with a decrease in neutrophil accumulation in the lung tissue
and the alveolar compartment. The mechanism mediating
protection may involve the blockade of the transcription
factor NF-B, and this blockade appears to result in a
decreased expression of proinflammatory cytokines.
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Discussion
Dr Stuart W. Jamieson (San Diego, Calif). Few here will
remember that for the first clinical lung transplants, 20 years ago
now, all the donors were brought into the adjoining room for
harvesting of the heart-lung block. Needless to say this caused
considerable tactical problems, particularly in flying bodies across
state lines. It was clear to everybody that better understanding of
lung injury would be required to make clinical lung transplantation
an effective therapy. In late 1982 we started to use modified
Euro-Collins solution for lung protection, and the first long-dis-
tance lung procurement was done in December that year. Our
group in San Diego has continued to use that solution exactly as
formulated then, and we are comfortable with ischemic times as
long as 8 hours. But most things could probably be improved, and
this is important work that is well presented. It confirms that, as
with other organs that are devastated by reperfusion injury, calci-
um-dependent signaling is an important component in the devel-
opment of lung ischemia-reperfusion injury, which has been char-
acterized here by alterations in lung vascular permeability, tissue
MPO accumulation, and leukocyte transendothelial migration.
There is also reduction in the expression of cytokine messenger
RNA, which suggests an inhibitory effect on the calcineurin-
dependent expression of NF-B. That calcineurin inhibitors were
ineffective when administered at the time of or after reperfusion
further suggests interruption of an early event in the evolution of
reperfusion injury, if not of a response to hypoxia itself.
I would appreciate your comments on some areas. Do you have
direct evidence regarding the site of the calcineurin effect, whether
this is on leukocytes, endothelial cells, or both? If the effect is
Cardiopulmonary Support and Physiology Krishnadasan et al
766 The Journal of Thoracic and Cardiovascular Surgery ● April 2002
CSP
restricted to leukocytes, then most teams are probably already
benefitting from this therapy, because the recipient has usually
been already treated some hours before reperfusion. But if the
effect is primarily on the vascular endothelium, then this would
suggest that the donor ought to be treated.
Significant immunomodulation is unlikely to occur with single
doses of CSA or FK-506, and you make the point that these agents
exhibit differential antiinflammatory and immunomodulatory ef-
fects. Do you think that this dichotomy in effects could be related
to different sensitivities to the drugs of discrete populations of
leukocytes? On a related issue, what do you believe is the key
effector cell in this reaction?
Finally, the ribonuclease protection assay demonstrated a gen-
eralized decrease in inflammatory cytokine content with both
drugs. Have you demonstrated functional roles for these cytokines
in lung ischemia-reperfusion injury?
Dr Krishnadasan. Thank you for those insightful comments.
With respect to your first question, about calcineurin’s effects on
leukocytes and endothelial cells, the in vitro data to date suggests,
and studies have mostly concentrated on T lymphocytes, that CSA
and tacrolimus do have effects at high doses on those types of
cells. For inflammatory cells, such as alveolar macrophages and
neutrophils, the lower doses of CSA and tacrolimus seem to be
effective at blocking NF-B activation.
The interesting question of course is what happens to the
endothelial cell, and obviously in our whole-organ preparations we
cannot sort out what is happening in individual cells. Mulligan’s
laboratory has turned the opposite way and looked at what is going
on in vitro, and it appears that in fact the endothelial cell does play
an important role in these reactions. Verrier’s laboratory for the
last 10 or 15 years also has been doing work indicating that the
endothelial cell may be the first cell that is activated. This moves
to your second question about the potential effector cell.
We believe that the effector cell in the lung is probably the
alveolar macrophage. It is situated in a position that would make
it ideally suited to driving the reaction, and in fact when you
compare pulmonary artery endothelial cells’ and alveolar macro-
phages’ effects on hypoxia and reoxygenation in vitro, we find that
alveolar macrophages have a much more robust response to hy-
poxic stimulus. This makes sense, because the alveolar macro-
phage is a monocytic cell that produces all the relevant cytokines
that we discussed. Again, this dovetails into your third question
regarding the ribonuclease protection assay and the functional
roles of the cytokines.
Much of my first year in the laboratory was spent defining
functional roles for various cytokines, among them TNF-, IL-1,
some of the chemokines, macrophage inflammatory protein-1,
MIP-2, membrane cofactor protein 1, and some TH2 cytokines
such as IL-4 and IL-10. It appears that the most protection that we
are afforded by single cytokine blockade is about a 45% decrease
in lung permeability, which if you compare that with the data that
I presented today suggests that the effects of CSA and tacrolimus
are more proximal in the cascade and are pretty remarkable com-
pared with single-cytokine blockade.
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